drugset / Trial / NCT00048087
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.
Timeline
- Start
- 2002-08
- Primary completion
- 2003-07
- Completion
- 2003-07
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |